OMER

Business Context and Reporting Period

Company: Omeros Corporation (OMEROS CORP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on inflammation and central nervous system disorders. The company is classified as a "Development Stage Company" with no products approved for commercial sale. Its primary revenue source is grant funding. Key product candidates include OMS103HP (PharmacoSurgery platform for arthroscopic surgery), OMS302 (ophthalmological), and OMS201 (urological).

Key Financial Metrics

Note: All financial figures are in thousands unless otherwise noted. The company reported a net loss per share of $(0.31) for Q1 2010.

Material Changes vs. Prior Period

• Revenue Increase: Grant revenue increased to $378,000 from $197,000, primarily due to additional recognition of National Institutes of Health (NIH) grants.
• Expense Growth: Total operating expenses rose by approximately $1.4 million to $6.8 million. Research and Development (R&D) expenses increased by $1.1 million to $5.1 million, driven by higher contract service costs and a one-time $500,000 payment to Affitech AS to terminate future royalty obligations.
• Investment Income Decline: Investment income dropped to $17,000 from $81,000 due to lower market interest rates.
• Interest Expense Reduction: Interest expense decreased to $452,000 from $590,000 due to a lower principal balance on notes payable to BlueCrest Venture Finance.
• Cash Position: Cash and cash equivalents remained relatively stable at $814,000, while short-term investments decreased from $59.5 million to $50.3 million, reflecting sales of investments to fund operations.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Clinical Milestones: The company expects to release results from its Phase 3 clinical trial for OMS103HP (ACL reconstruction) in the second half of 2010. Commercialization is not expected before 2011 at the earliest.
• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($51.1 million total) are sufficient to fund operations for at least the next 12 months.
• Future Losses: The company anticipates net losses will increase in 2010 as it advances clinical trials and expands R&D efforts.

Material Risks and Contingencies:

• Legal Proceedings: A lawsuit filed by former CFO Richard J. Klein alleges violations of the Federal False Claims Act and wrongful termination. The company intends to defend vigorously; the outcome is uncertain.
• Regulatory Risk: Success depends heavily on FDA approval of OMS103HP. The FDA has questioned the study design for efficacy and the contribution of active ingredients in combination drugs.
• Capital Requirements: The company has no commitments for future external funding. If capital resources are insufficient, it may need to delay programs or seek dilutive equity financing.
• Debt Covenants: The company has a $17.0 million debt facility with BlueCrest. Default could trigger immediate repayment and loss of pledged assets.

Key Facts for Investor Verification

• Phase 3 Trial Timing: Verify the timeline for the release of OMS103HP Phase 3 results (expected H2 2010) and potential delays.
• Liquidity Runway: Confirm the sufficiency of the $51.1 million cash/investment balance against projected burn rates for the next 12 months.
• Legal Exposure: Monitor the status of the litigation filed by former CFO Richard J. Klein regarding NIH grant claims and wrongful termination.
• Debt Obligations: Review the terms of the BlueCrest loan, specifically the 12.5% interest rate, collateral requirements, and potential for acceleration upon a "material adverse effect."
• Revenue Model: Acknowledge that the company has no product revenue and relies entirely on grants and potential future collaborations or sales.